Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience

Rughani, Milap G.; Swan, Marc C.; Adams, Titus S.; Middleton, Mark R.; Ramcharan, Roger; Pay, A.D.; Birch, Jeremy; Coleman, David; Cassell, Oliver

doi:10.1016/j.bjps.2011.05.001

Cited by 18 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with previously published data, where complication rates between 1.8 and 33% were reported, in our study complications occurred in 20.4% of the patients. A total of 2.1% of the patients in our study developed postoperative wound infections, which is in line with previous data, reporting infection rates between 0.3 and 19% . In the literature, the seroma rates range from 0 to 38%, corresponding to the 19.6% seroma rate in our study.…”

Section: Discussionsupporting

confidence: 91%

“…A total of 2.1% of the patients in our study developed postoperative wound infections, which is in line with previous data, reporting infection rates between 0.3 and 19%. 10,11 In the literature, the seroma rates range from 0 to 38%, 4,12 corresponding to the 19.6% seroma rate in our study. Similar seroma incidences were also reported in SLNB for breast cancer.…”

Section: Discussionsupporting

confidence: 54%

See 1 more Smart Citation

Predicting risk for seroma development after axillary or inguinal sentinel lymph node biopsy in melanoma patients

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 54%

Predicting risk for seroma development after axillary or inguinal sentinel lymph node biopsy in melanoma patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Current studies have identified phenotypic factors such as increased tumor thickness [7,[13][14]18,[26][27][28][29][30], presence of ulceration [7,[13][14][26][27][29][30][31][32], increased number of mitoses [26,29,31] and increased patient age [13][14]18,27] as risk factors for tumor recurrence. Attempts to further identify high-risk melanoma patients using molecular studies for melanoma markers such as in situ PCR and RT-PCR for MART1, MAGE-3, GalNAc-T and PAX3 mRNA have had some success, but suffer from the challenges of both broadly deploying complex technology as well SyStematic Review Hodges, Jones, Jones et al…”

Section: Melanoma Biology and Recurrencementioning

confidence: 98%

Analysis of Melanoma Recurrence Following a Negative Sentinel Lymph Node Biopsy

Hodges

Jones

et al. 2015

Melanoma Manag.

View full text Add to dashboard Cite

Little attention has been paid to the characteristics and outcomes of patients who experience distant, local or regional recurrence of melanoma following a negative sentinel lymph node biopsy. This article aims to review the published literature on the topic and presents some general summaries regarding this patient population. Patients who experience a disease recurrence following a negative sentinel lymph node biopsy have a worse overall survival compared with patients with a positive sentinel lymph node biopsy. The implications and possible explanations for these findings are discussed in order to both underscore the need for in-depth investigation of local, regional or distant melanoma recurrence among patients following a true negative sentinel lymph node biopsy, as well as increased efforts to minimize the rate of false negative sentinel lymph node biopsies.

show abstract

“…8-10 The improvement in outcome is especially marked for melanomas with a Breslow depth greater than 4 mm. 15 Overall survival remains the same, however, and no intervention to date has been shown to improve the overall survival benefit of patients with melanoma. 2…”

mentioning

confidence: 99%

Metastatic Melanoma in Sentinel Node–Negative Patients: The Ottawa Experience

2017

View full text Add to dashboard Cite

The rate of metastatic melanoma following negative SLNB at long-term follow-up at the ORCC is higher than the upper limit of rates reported in the literature (6%-24%). The reason for this is multifactorial, and the long follow-up period of 5 years allowed for detection of metastatic disease at a mean of 3.9 years. Long-term prognosis may be guarded in node-negative patients with a primary cutaneous melanoma, and surveillance by a multidisciplinary team is crucial.

show abstract

Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience

Cited by 18 publications

References 20 publications

Predicting risk for seroma development after axillary or inguinal sentinel lymph node biopsy in melanoma patients

Predicting risk for seroma development after axillary or inguinal sentinel lymph node biopsy in melanoma patients

Analysis of Melanoma Recurrence Following a Negative Sentinel Lymph Node Biopsy

Metastatic Melanoma in Sentinel Node–Negative Patients: The Ottawa Experience

Contact Info

Product

Resources

About